Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GX-03

Other · developed by Turn Therapeutics

Phase 2 Most advanced trial (none active)
TTRX Developer
1 Registered trials

What is GX-03?

GX-03 (Hexagen Antimicrobial) is an agent studied in COVID-19. The only source text available describes its dosing as matching that used in Bactroban Nasal studies, and gives no information on its mechanism or composition.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Hexagen Antimicrobial
Drug type
Other
Therapy area
Infectious disease
Developer
Turn Therapeutics (TTRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04951349 Phase 2 Covid19 Completed TTRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Covid19

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TTRX page.

Follow TTRX, the company behind GX-03

See TTRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TTRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.